25.60

0.19% -0.05

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $25.60, with a volume of 1.44M. It is down -0.19% in the last 24 hours and down -13.66% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$25.65

Open:

$25.21

24h Volume:

1.44M

Relative Volume:

0.37

Market Cap:

$4.32B

Revenue:

$56.99M

Net Income/Loss:

$-107.23M

P/E Ratio:

-31.22

EPS:

-0.8199

Net Cash Flow:

$-142.55M

1W Performance:

-5.43%

1M Performance:

-13.66%

6M Performance:

+98.45%

1Y Performance:

+269.94%

1-Day Range:

$24.75

$25.70

1-Week Range:

$24.75

$28.09

52-Week Range:

$6.25

$34.39

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

137

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	25.60	4.31B	56.99M	-107.23M	-142.55M	-0.8199
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-26	Initiated	Canaccord Genuity	Buy
Feb-23-26	Initiated	Mizuho	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

02:07 AM

Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat

02:07 AM

Aug 14, 2026

Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan

Aug 14, 2026

Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan

Aug 14, 2026

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan

Aug 14, 2026

Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan

Aug 14, 2026

Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan

Aug 14, 2026

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 14, 2026

Aug 13, 2026

Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - Moomoo

Aug 13, 2026

Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 13, 2026

Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media

Aug 13, 2026

Aug 12, 2026